Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor (ABBIL1TY MELANOMA-07)
Sponsor: Genmab
A PHASE2 clinical study on Cutaneous Melanoma and Metastatic Cutaneous Melanoma (Stage IV), this trial is ongoing. The trial is conducted by Genmab and has accumulated 9 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Active Not Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2025 — Aug 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Genmab
For direct contact, visit the study record on ClinicalTrials.gov .